Related references
Note: Only part of the references are listed.In Vitro Antifungal Susceptibility of the Emerging Multidrug-Resistant Pathogen Candida auris to Miltefosine Alone and in Combination with Amphotericin B
Yongqin Wu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Nanocarriers Provide Sustained Antifungal Activity for Amphotericin B and Miltefosine in the Topical Treatment of Murine Vaginal Candidiasis
Fernanda Walt Mendes da Silva de Bastiani et al.
FRONTIERS IN MICROBIOLOGY (2020)
Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris
Thayna Lopes Barreto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Combination Therapy for Invasive Fungal Infections
Spencer J. Livengood et al.
CURRENT FUNGAL INFECTION REPORTS (2020)
Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis
Cristina de Castro Spadari et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice
Zahra Kavian et al.
ACTA TROPICA (2019)
Resistance mechanism and proteins in Aspergillus species against antifungal agents
Sonia Kumari Shishodia et al.
MYCOLOGY-AN INTERNATIONAL JOURNAL ON FUNGAL BIOLOGY (2019)
Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management
Shivaprakash M. Rudramurthy et al.
JOURNAL OF FUNGI (2019)
Miltefosine-based regimen as salvage therapy in Lomentospora prolificans bone and joint infection
L. Quaesaet et al.
MEDECINE ET MALADIES INFECTIEUSES (2018)
Ecology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus species
Caroline Paulussen et al.
MICROBIAL BIOTECHNOLOGY (2017)
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
Thomas F. Patterson et al.
CLINICAL INFECTIOUS DISEASES (2016)
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Dominique Sanglard
FRONTIERS IN MEDICINE (2016)
In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp.
Fabrice Compain et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2015)
In Vitro Combination of Voriconazole and Miltefosine against Clinically Relevant Molds
S. Imbert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics
J. A. Trubiano et al.
MYCOSES (2014)
In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens
Chayanika Biswas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Galleria mellonella larvae as an infection model for group A streptococcus
Jacelyn M. S. Loh et al.
VIRULENCE (2013)
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Thomas P. C. Dorlo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Histopathology of cutaneous sporotrichosis in Rio de Janeiro: a series of 119 consecutive cases
Leonardo Pereira Quintella et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2011)
Pulmonary aspergillosis: a clinical review
M. Kousha et al.
EUROPEAN RESPIRATORY REVIEW (2011)
Scedosporium prolificans Osteomyelitis in an Immunocompetent Child Treated with a Novel Agent, Hexadecylphospocholine (Miltefosine), in Combination with Terbinafine and Voriconazole: A Case Report
Alison M. Kesson et al.
CLINICAL INFECTIOUS DISEASES (2009)
Hexadecylphosphocholine (Miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis
F Widmer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusatium spp.
A Philip et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro synergy of caspofungin and itraconazole against Aspergillus spp.:: MIC versus minimal effective concentration end points
I Shalit et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.:: NCCLS Collaborative Study
A Espinel-Ingroff et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Share Paper
